Cargando…
The cost‐effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain
BACKGROUND: Invasive mould diseases are associated with high morbidity, mortality and economic impact. Its treatment is often started prior to differential pathogen diagnosis. Isavuconazole is approved for treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) when amphotericin‐B is...
Autores principales: | Azanza, José Ramón, Grau, Santiago, Vázquez, Lourdes, Rebollo, Pablo, Peral, Carmen, López‐Ibáñez de Aldecoa, Alejandra, López‐Gómez, Vanessa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894146/ https://www.ncbi.nlm.nih.gov/pubmed/32989796 http://dx.doi.org/10.1111/myc.13189 |
Ejemplares similares
-
Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain
por: Grau, Santiago, et al.
Publicado: (2016) -
Antibacterials/isavuconazole/voriconazole: Lack of efficacy: case report
Publicado: (2020) -
Amphotericin-B-liposomal/isavuconazole/voriconazole: Lack of efficacy: 6 case report
Publicado: (2022) -
Isavuconazole/piperacillin/tazobactam/voriconazole: Drug-induced liver injury: case report
Publicado: (2022) -
Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
por: Harrington, Rachel, et al.
Publicado: (2016)